low - Pre-revenue biotechs are largely insulated from GDP fluctuations as they generate no sales. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) clinical trial enrollment if patients defer elective procedures, (3) partnership valuations if pharma acquirers reduce M&A activity. DMD is a severe progressive disease where treatment decisions are not discretionary, providing demand stability post-approval.

Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (estimated 2029+ for SGT-003 revenue). Clinical-stage biotechs with no earnings trade primarily on NPV of pipeline assets, making them sensitive to risk-free rate changes. Higher rates also increase financing costs for future capital raises and make cash-burning growth stocks less attractive relative to fixed income. However, Solid's minimal debt (0.10 D/E) limits direct interest expense impact. The 23% stock rally over 3 months suggests rate stabilization expectations may be supporting valuation.

growth/speculative - Attracts biotech-focused hedge funds, venture capital crossover funds, and retail investors seeking asymmetric risk/reward from binary clinical outcomes. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. The 3.8% one-year return with high volatility (23% gain in 3 months, -8.8% over 6 months) reflects event-driven trading around clinical milestones. Typical holders include specialized healthcare funds willing to underwrite 5-7 year development timelines and accept 70-90% downside risk for potential 300-500% upside if SGT-003 succeeds.